ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AKTX
KYNB (32) COCP (36) ACTU (35) MCRB (40) ⌘ Pro Terminal →

Akari Therapeutics plc ADS (AKTX) — RQD Stock Rating Cockpit

$7.84 -4.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.76

Akari Therapeutics plc ADS (AKTX) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $18.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AKTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AKTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Akari Therapeutics plc ADS (NASDAQ: AKTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $7.84 (-4.85% 1D, market cap $18.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AKTX ranks #547 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AKTX compare to KYNB and COCP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AKTX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M) and COCP (Cocrystal Pharma Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $19.2M). Among the 5-stock peer group, AKTX leads on earnings multiple (N/A) while AKTX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AKTX?
▼

Per AKTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001541157), Akari Therapeutics plc ADS generated $48.4M in revenue (-20.2% YoY), -$17.3M in net income, and -$10.6M in free cash flow against $47.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.76 (-1.06%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (8)Whales (5)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$35 Bull$7 Base$6 Bear
📬 FREE AKTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AKTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY AKTX SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (24% of score)

FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 47.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
45
Grade D$7.90+17.6% Next Q
Q2 (-2Q)
42
Grade D$9.29-7.6% Next Q
Q3 (-1Q)
40
Grade D$8.58-8.6% Next Q
Current
37
Grade D-$7.84-8.1% Hist 90D α
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AKTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AKTX currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.30) and Max Pain ($8.23) forces dealer call-delta covering toward $35.28.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AKTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AKTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
47.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE16% OF RANGE
L: $3$7.84H: $34
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on AKTX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (32)

10/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like AKTX
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AKTX)

  • ✓Walkthrough of AKTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AKTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.88%⚡ TESTING RESISTANCE
2026-11-03O $8.00H $8.24L $7.84C $7.84VOL 45.8K
RES: $9.17SUP: $7.15SMA50: $9.30SMA200: $9.03
$31.16$23.53$15.91$8.28$0.65RES $9.17SUP $7.15$7.842026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AKTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AKTX Butterfly Map → + Track AKTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -20.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AKTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AKTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AKTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AKTX)

Health Care Rank #547 of 1015 ⚔️ KYNB vs AKTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AKTX vs. KYNB, COCP, ACTU, MCRB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Akari Therapeutics plc ADS (AKTX) ranks #547 by composite RQD confidence (37/100, grade D-) and #833 by equity capitalization ($18.8M). Within this direct 5-issuer industry benchmark cohort, AKTX leads on earnings valuation at N/A trailing P/E, while AKTX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MCRB currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with AKTX at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AKTX ACTIVE
Akari Therapeutics plc ADS
D- 37/100 — — -35.0% -4.85% $18.8M Benchmark Subject
KYNB
Kyntra Bio Inc.
E 32/100 — 91.4% -35.0% -2.41% $18.5M /kynb-vs-aktx →
COCP
Cocrystal Pharma Inc.
D- 36/100 — — -35.0% +6.53% $19.2M /cocp-vs-aktx →
ACTU
Actuate Therapeutics Inc.
D- 35/100 — — -35.0% +2.06% $18.4M /actu-vs-aktx →
MCRB
Seres Therapeutics Inc.
D- 40/100 — — -35.0% +3.39% $17.8M /mcrb-vs-aktx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001541157 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Akari Therapeutics plc ADS (AKTX) reported GAAP revenue of $48.4M (-20.2% vs. FY2024 revenue of $60.6M , and +13048.4% cumulative change since FY2023) , GAAP net income of -$17.3M, operating cash flow of -$10.6M, and free cash flow of -$10.6M (+15.8% YoY). On the balance sheet, AKTX closed FY2025 with $47.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $48.4M -$17.3M -$10.6M -$10.6M $47.9M —
FY2024 (FY) 2024-12-31 $60.6M -$19.8M -$12.6M -$12.6M $50.6M —
FY2023 (FY) 2023-12-31 $367.9K -$10.0M -$16.4M -$16.4M — —

3. AKTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AKTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Akari Therapeutics plc ADS (NASDAQ: AKTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $7.84 (-4.85% 1D, market cap $18.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AKTX ranks #547 in composite RQD confidence.

How does AKTX compare to KYNB and COCP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AKTX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M) and COCP (Cocrystal Pharma Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $19.2M). Among the 5-stock peer group, AKTX leads on earnings multiple (N/A) while AKTX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AKTX?

Per AKTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001541157), Akari Therapeutics plc ADS generated $48.4M in revenue (-20.2% YoY), -$17.3M in net income, and -$10.6M in free cash flow against $47.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AKTX trading relative to its 50-day, 200-day, and 52-week technical levels?

AKTX last traded at $7.84 (-4.85% on volume of 11,865 shares), positioning the stock -15.70% below its 50-day simple moving average ($9.30) and -13.18% below its 200-day simple moving average ($9.03). Across its 52-week range of $3.02 to $33.60, AKTX sits at the 15.8% percentile with a 14-day RSI of 47.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.86 to $8.82).

Direct Sub-Reports: AKTX RQD Cockpit AKTX 12M Forecast AKTX Earnings & Move AKTX Dividends & DRIP AKTX Insiders & 13F AKTX Whale Options AKTX Profit Sankey AKTX News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

AKTX — Akari Therapeutics plc ADS: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Akari Therapeutics plc ADS (AKTX) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $7.84 (-4.85% 1D, market capitalization $18.8M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Akari Therapeutics plc ADS (AKTX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is reported as $0.0B, while the market data shows $18.3M. The company reported — of revenue in FY 2025 and FY 2024, and $0.4M in FY 2023. — for product lines, customers, or revenue model specifics.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Akari Therapeutics plc ADS (AKTX) reported $48.4M in annual revenue (up from $60.6M in FY2024, -20.2% YoY) and -$17.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($367.9K revenue, -$10.0M net income) through FY2025, AKTX scaled operating cash flow to -$10.6M and free cash flow to -$10.6M, backed by $47.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $3.02 – $33.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream suppliers, downstream customers, or sector correlation mappings beyond the Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification.

  • Key Question #1: Can AKTX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $48.4M and free cash flow of -$10.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is AKTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AKTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Akari Therapeutics plc ADS (AKTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AKTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AKTX Bull vs. Bear Conversation Board — What's Your Call at $7.84?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AKTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AKTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $9.72 (+18.0%)
📌 Pinned Debate

The Altman Z-Score of 2.5 and Debt/Equity of 0.5 suggest the balance sheet is not yet distressed despite cash burn.

Here is why I am bullish on AKTX here at $8.24: The Altman Z-Score of 2.5 and Debt/Equity of 0.5 suggest the balance sheet is not yet distressed despite cash burn.. Compare AKTX's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $7.83 are getting bought.

ArenaChamp_24 🐂 BULL

@DeltaGamma_99 Agree on the RQD 37/100 quality, though with 1.0 beta I'm scaling in with half-size at $8.24 and keeping dry powder in case we test $7.66.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $6.92 (-16.0%)
Spot @ $8.24

The company posted operating losses in every reported period with ROIC of -35%, zero revenue in FY 2025 and FY 2024, and a Piotroski F-

Sitting on the sidelines or leaning short AKTX above $8.24. The company posted operating losses in every reported period with ROIC of -35%, zero revenue in FY 2025 and FY 2024, and a Piotroski F-Score of 2/9.. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $33.60.

LIVE TAPE